Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 2, 2013

Ovarian Cancer Treatment Milestone Earns Array BioPharma $5M

  • Array BioPharma achieved a $5 million milestone after the start of its Phase III clinical trial in patients with low-grade serous ovarian cancer (LGSOC).

    The study, called MILO (MEK Inhibitor in Low-Grade Serous Ovarian Cancer), is a multinational, randomized Phase III trial that aims to evaluate MEK162 against physician's choice of standard chemotherapy treatments in 300 patients with recurrent or persistent LGSOC following at least one prior platinum-based chemotherapy regimen and no more than three lines of prior chemotherapy regimens. The primary endpoint is progression-free survival, and the key secondary endpoint is overall survival.

    MEK is a key protein kinase in the RAS/RAF/MEK/ERK pathway, and MEK162 is a small molecule MEK inhibitor that, according to Array, targets a key position in this pathway. Array invented MEK162 (formerly known as ARRY-162) and licensed worldwide rights to develop and commercialize the drug to Novartis in April of 2010. Under terms of that agreement, Array received an up-front and milestone payment of $45 million and was eligible to receive an additional $422 million if certain clinical, regulatory, and commercial milestones are achieved. Array achieved another milestone under this agreement back in April of 2011, receiving $10 million.

    Novartis recently detailed plans to initiate Phase III trials of MEK162 in both NRAS- and BRAF-mutant melanoma. All three trials will be conducted as part of the Novartis/Array co-development agreement.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Pharmacists and Prescription Drug Misuse Programs

Do you agree that pharmacists should make a greater effort to become more involved with prescription drug-monitoring programs?

More »